Apellis Pharmace Stock Price, News & Analysis

Apellis Pharmaceuticals (Nasdaq: APLS) will present at the Stifel 2025 Healthcare Conference on Wednesday, November 12, 2025 at 2:40 p.m. ET. The company said a live webcast will be posted on the Events and Presentations page of its Investors and Media website. A replay of the webcast will be available for approximately 90 days after the event.

Apellis (Nasdaq: APLS) reported third quarter 2025 results on October 30, 2025, with $458.6 million total revenue including a $275.0 million upfront from Sobi for a capped ex-U.S. royalty purchase on Aspaveli. Product sales included $150.9 million for SYFOVRE and $26.8 million for EMPAVELI in the U.S. EMPAVELI received FDA approval July 28, 2025 for C3G and primary IC-MPGN (12+), with launch activity showing 152 patient start forms by Sept 30, 2025.

SYFOVRE delivered ~101K doses (including ~15K free goods), total injections grew 4% QoQ, and SYFOVRE market share remained above an estimated 60%. Cash and equivalents were $479.2 million at Sept 30, 2025. Management expects existing cash plus product revenues to fund operations to sustainable profitability.

Apellis Pharmaceuticals (NASDAQ: APLS) announced new one-year Phase 3 VALIANT data for EMPAVELI (pegcetacoplan) in C3 glomerulopathy (C3G) and primary IC-MPGN presented at ASN Kidney Week on October 20, 2025. Key results: EMPAVELI sustained a 68% proteinuria reduction versus placebo (p<0.0001) at one year, with consistent effects irrespective of immunosuppressant use or baseline proteinuria. One-third of treated patients achieved complete proteinuria remission (UPCR ≤0.5 g/g) versus 3% on placebo at Week 26, maintained through one year. EMPAVELI stabilized eGFR and showed a safety profile consistent with prior data. Two anchored indirect treatment comparisons indicated EMPAVELI was superior to iptacopan on multiple proteinuria and composite renal endpoints, with noted methodological limitations for ITCs.

Apellis (Nasdaq: APLS) will host a conference call and webcast to discuss third quarter 2025 financial results on Thursday, October 30, 2025 at 8:30 a.m. ET.

Investors can pre-register to join by phone, and a live audio webcast plus slides will be available on the company’s Investors and Media "Events and Presentations" page. A replay of the webcast will be accessible for 90 days after the event.

Apellis describes itself as a global biopharmaceutical company focused on complement science with two C3-targeting medicines approved for four diseases; contact for investor inquiries is Eva Stroynowski at the company.

Apellis Pharmaceuticals (Nasdaq: APLS) announced its participation in three upcoming investor conferences in September 2025. The company's management will engage in webcast fireside chats at the Wells Fargo Healthcare Conference (September 3 at 8:45 a.m. ET), Cantor Global Healthcare Conference (September 4 at 8:35 a.m. ET), and Baird Global Healthcare Conference (September 9 at 10:15 a.m. ET).

All webcasts will be accessible through the company's website under the "Events and Presentations" page, with replays available for approximately 30 days after each event.

Apellis Pharmaceuticals (Nasdaq: APLS) reported Q2 2025 financial results, highlighting significant achievements including FDA approval of EMPAVELI for C3G and IC-MPGN treatment. The company generated $178.5 million in total revenue, with SYFOVRE contributing $150.6 million in U.S. net product sales.

Key developments include a $300 million royalty purchase agreement with Sobi for 90% of ex-U.S. EMPAVELI royalties and continued market leadership of SYFOVRE in GA treatment with 60% market share. The company reported a net loss of $42.2 million and cash position of $370 million, which combined with expected revenues and Sobi agreement funds, is anticipated to sustain operations until profitability.

Apellis Pharmaceuticals (Nasdaq: APLS) has received FDA approval for EMPAVELI® (pegcetacoplan) as the first treatment for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in patients 12 years and older.

The approval is based on the Phase 3 VALIANT study results showing three key achievements: a 68% reduction in proteinuria (p<0.0001), stabilization of kidney function (p=0.03), and substantial clearance of C3 deposits, with 71% of treated patients achieving complete clearance.

This breakthrough treatment targets rare kidney diseases affecting 5,000 people in the United States, where approximately 50% of patients progress to kidney failure within 5-10 years of diagnosis. The therapy demonstrated efficacy across both adolescent and adult patients, including those with post-transplant disease recurrence.

Apellis Pharmaceuticals (Nasdaq: APLS) announced it will host a conference call and webcast to discuss its second quarter 2025 financial results on Thursday, July 31, 2025, at 8:30 a.m. ET.

Investors can pre-register for the call, and a live audio webcast with accompanying slides will be available through the company's website. The webcast replay will be accessible for 90 days after the event.

Apellis Pharmaceuticals (Nasdaq: APLS) announced that five abstracts highlighting SYFOVRE® (pegcetacoplan injection) data have been accepted for oral presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting from July 30 - August 2 in Long Beach, California.

The presentations will showcase SYFOVRE's efficacy and safety profile in treating geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The data demonstrates SYFOVRE's ability to slow GA progression with as few as six doses per year. The abstracts cover various aspects including baseline characteristics, early vs. delayed treatment results, clinical utility in bilateral GA, combination therapy with anti-VEGF treatments, and the impact of AREDS supplements on GA progression.

SYFOVRE is notable as the first-ever approved therapy for GA, a condition affecting over one million Americans and five million people worldwide.